Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.HSAC · Entity 3632 | Director | May 09, 2019 | May 10, 2019 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director · President and Head of R&D | July 10, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date May 09, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of Health Sciences Holdings, LLC. | 20,000 |
Reported balance
Holding disclosure · report date 2019-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Taysha Gene Therapies, Inc.
Report date July 10, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 936,410 |
Reported balance
After 2026-07-10 transaction · row 1
1 source rowRow 1 · 2026-07-10 · Sale · Disposed 200,000 · Balance 936,410 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Disposed 3,800 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 3,800 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.47 · Expires 2025-09-14 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 178,494 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.61 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 37,750 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.24 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 25,200 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Performance Stock Units (Right to Buy)SEC Table II · derivative / convertible security · Expires 2028-05-15 | Direct | 9,906 |
Reported balance
After 2018-05-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-15 · Grant · Acquired 9,906 · Balance 9,906 F4: On March 20, 2017, the Reporting Person was awarded a performance stock unit (the "PSU") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied. F5: Immediately exercisable. |
| Performance Stock Units (Right to Buy)SEC Table II · derivative / convertible security · Expires 2028-05-15 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-15 · Disposition to issuer · Disposed 9,906 · Balance 0 F4: On March 20, 2017, the Reporting Person was awarded a performance stock unit (the "PSU") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied. F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F6: Pursuant to the Merger Agreement, each outstanding PSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock subject to the PSU. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 3,800 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
F4: On March 20, 2017, the Reporting Person was awarded a performance stock unit (the "PSU") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied.
F5: Immediately exercisable.
F6: Pursuant to the Merger Agreement, each outstanding PSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock subject to the PSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 10, 2026 22:54 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 200,000 | $6.24 | $1,248,000.00 |
DisclosureSEC source: 0001665124-26-000013 · form4-07102026_100732.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 936,410 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001193125-26-267504 · ownership.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 20:33 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,021 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001665124-26-000011 · form4-04132026_080454.xml · derivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,920 Underlying: Common Stock · 19,021 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 20:33 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 200,000 | $4.46 | $892,000.00 |
DisclosureSEC source: 0001665124-26-000011 · form4-04132026_080454.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,136,410 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 20:33 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionCommon Stock | 19,021 | $1.71 | $32,525.91 |
DisclosureSEC source: 0001665124-26-000011 · form4-04132026_080454.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,336,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 26,918 | $4.61 | $124,091.98 |
DisclosureSEC source: 0001665124-26-000008 · form4-01272026_040105.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,317,389 F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 89,132 | $4.75 | $423,377.00 |
DisclosureSEC source: 0001665124-26-000008 · form4-01272026_040105.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,344,307 F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 274,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001665124-26-000002 · form4-01142026_040101.xml · derivative · entry 7 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,000 Underlying: Common Stock · 274,000 shares Expires 2036-01-12 F6 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 88,676 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001665124-26-000002 · form4-01142026_040101.xml · derivative · entry 6 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,941 Underlying: Common Stock · 88,676 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 111,324 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001665124-26-000002 · form4-01142026_040101.xml · derivative · entry 5 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,359 Underlying: Common Stock · 111,324 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 427,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 4 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,433,439 F3 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 200,000 | $4.71 | $942,000.00 |
DisclosureSEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,006,439 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionCommon Stock | 88,676 | $1.71 | $151,635.96 |
DisclosureSEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,206,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionCommon Stock | 111,324 | $0.70 | $77,804.34 |
DisclosureSEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,117,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 260,047 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · derivative · entry 8 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,617 Underlying: Common Stock · 260,047 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 260,047 | $4.51 | $1,172,811.97 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 5 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,006,439 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionCommon Stock | 260,047 | $1.71 | $444,680.37 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 4 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,266,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 39,953 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · derivative · entry 7 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 823,664 Underlying: Common Stock · 39,953 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 70,172 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · derivative · entry 6 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,683 Underlying: Common Stock · 70,172 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 110,125 | $4.75 | $523,093.75 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,006,439 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2). Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionCommon Stock | 39,953 | $1.71 | $68,319.63 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,116,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 01:58 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionCommon Stock | 70,172 | $0.70 | $49,043.21 |
DisclosureSEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 41,150 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001415889-25-024369 · form4-09122025_040917.xml · derivative · entry 3 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,855 Underlying: Common Stock · 41,150 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 200,000 | $3.23 | $646,000.00 |
DisclosureSEC source: 0001415889-25-024369 · form4-09122025_040917.xml · nonDerivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,006,439 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.165 to $3.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Exercise / conversionCommon Stock | 41,150 | $0.70 | $28,759.74 |
DisclosureSEC source: 0001415889-25-024369 · form4-09122025_040917.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,206,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 57,054 | $2.85 | $162,603.90 |
DisclosureSEC source: 0001415889-25-022750 · form4-08222025_040806.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,165,289 F1 · shares: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:25 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000950170-25-086238 · ownership.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2035-06-12 F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:36 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 324,500 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001415889-25-000597 · form4-01032025_100136.xml · derivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,500 Underlying: Common Stock · 324,500 shares Expires 2035-01-02 F2 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:36 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 324,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000597 · form4-01032025_100136.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,222,343 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:08 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 34,400 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0000950170-24-072998 · ownership.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 34,400 shares Expires 2034-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:42 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 863,617 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000809 · doc4.xml · derivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,617 Underlying: Common Stock · 863,617 shares Expires 2034-01-02 F2 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:42 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 863,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000809 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897,843 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:47 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 334,005 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058973 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,005 Underlying: Common Stock · 334,005 shares Expires 2033-12-14 F1 · derivative.exercise_date: The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:19 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0000899243-23-015002 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2033-06-06 F1 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:44 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 5,000 | $0.68 | $3,400.00 |
DisclosureSEC source: 0001209191-23-030661 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,226 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.682 to $0.6879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:51 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 790,093 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-001019 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,093 Underlying: Common Stock · 790,093 shares Expires 2032-12-30 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0000899243-22-038681 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2032-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:39 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-038690 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2032-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:11 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-035461 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 14:21 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 10,000 | $8.01 | $80,100.00 |
DisclosureSEC source: 0001209191-22-006652 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,226 Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:04 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $25.04 | $0.00 |
DisclosureSEC source: 0001209191-21-042110 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001209191-21-041934 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:37 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionSeries B Preferred Stock · Derivative | 17,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052460 · doc4.xml · derivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:37 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionCommon Stock | 19,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052460 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:12 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052114 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2030-09-23 F1 · derivative.exercise_date: The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:18 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001209191-20-037576 · doc4.xml · derivative · entry 2 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-16 F2 · derivative.exercise_date: This option was granted on June 16, 2020 to members of the Clinical Committee of the Board of Directors and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. F2 · derivative.underlying_shares: This option was granted on June 16, 2020 to members of the Clinical Committee of the Board of Directors and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:18 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001209191-20-037576 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 16, 2020 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:30 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 32,258 | $4.65 | $149,999.70 |
DisclosureSEC source: 0001209191-19-043487 · doc4.xml · nonDerivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,258 Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-19-037123 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: This option was granted on June 13, 2019 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:06 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 17,240 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031204 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,240 Underlying: Common Stock · 17,240 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests as to one-third of the total number of shares on each of September 12, 2019, September 12, 2020, and September 12, 2021, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.